ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Novartis AG

Novartis AG (NVS)

96.73
0.85
(0.89%)
Closed March 28 04:00PM
96.00
-0.73
(-0.75%)
After Hours: 07:12PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
96.00
Bid
-
Ask
-
Volume
1,524,700
96.15 Day's Range 97.20
0.00 52 Week Range 0.00
Market Cap
Previous Close
95.88
Open
96.31
Last Trade
2
@
96.73
Last Trade Time
Financial Volume
$ 147,543,960
VWAP
96.7692
Average Volume (3m)
-
Shares Outstanding
2,044,034,000
Dividend Yield
-
PE Ratio
13.28
Earnings Per Share (EPS)
7.27
Revenue
54.11B
Net Profit
14.85B

About Novartis AG

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, ca... Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Basel, Che
Founded
1970
Novartis AG is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NVS. The last closing price for Novartis was $95.88. Over the last year, Novartis shares have traded in a share price range of $ 0.00 to $ 0.00.

Novartis currently has 2,044,034,000 shares outstanding. The market capitalization of Novartis is $197.27 billion. Novartis has a price to earnings ratio (PE ratio) of 13.28.

NVS Latest News

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

  As filed with the Securities and Exchange Commission on February 15, 2024  Registration No. 333-250207       UNITED STATES SECURITIES AND EXCHANGE...

Form SC TO-C - Written communication relating to an issuer or third party

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE TO-C (Rule 14d-100)   TENDER OFFER STATEMENT UNDER...

Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More

Boeing (NYSE:BA) – The FAA announced that 94% of Boeing 737 MAX 9 planes have returned to service after a suspension caused by an air emergency. The inspections included a detailed review...

Form SC TO-C - Written communication relating to an issuer or third party

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE TO-C (Rule 14d-100)   TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 6-K     REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 OF THE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 6-K     REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 OF THE SECURITIES EXCHANGE ACT...

Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More

Walmart (NYSE:WMT) – Walmart announced a 3-for-1 stock split as part of its review of trading levels and spread. This will increase the shares in circulation to approximately 8.1 billion...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

NVS Discussion

View Posts
Monksdream Monksdream 3 months ago
NVS new 52 week high
👍️0
Monksdream Monksdream 3 months ago
NVS new 52 week high
👍️0
Monksdream Monksdream 3 months ago
NVS new 52 week high
👍️0
1jas 1jas 7 months ago
have you seen yesterday that enzolytics pharm announced that they now have a CURE for hiv/aids called clone3.?
👍️0
ernie44 ernie44 8 months ago
its a home run ---or is it just the runs

https://apis.mail.yahoo.com/ws/v3/mailboxes/@.id==VjN-cV7LhC8rx0EcG5-z9RhWgRsQvGZwTs2qwUxoYR9UStj84lOVi7ZIeMO8HFiplsA65ZbE_cF9gB9A2TSm5APqCg/messages/@.id==AA43g3BH-2gCZMlFEQgiCNhLPmU/content/parts/@.id==2/thumbnail?appid=YMailNorrin&downloadWhenThumbnailFails=true&pid=2
👍️0
awesomed007 awesomed007 8 months ago
https://www.prnewswire.com/news-releases/dtx-pharma-announces-acquisition-by-novartis-301877974.html. I have cmt. Getting closer to 1st fda approved treatment, hopeful!!!
👍️0
subslover subslover 2 years ago
Former Head of Novartis Respiratory and Allergy Medicine to Advise Clinical Stage Stem Cell Company on COVID-19 and COPD Programs
https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2224788
👍️0
FACT-MASTER FACT-MASTER 2 years ago
https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients
👍️0
FACT-MASTER FACT-MASTER 2 years ago
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma
👍️0
FACT-MASTER FACT-MASTER 2 years ago
Novartis also has a collaboration agreement with TScan Therapeutics for development of TCR-T cancer technology, one of the latest and promising therapeutics that could accompany CAR-T.

https://ir.tscan.com/news-releases/news-release-details/tscan-announces-collaboration-novartis-discovery-and-development

TScan entering clinical Phase 1 in 1H 2022.
👍️0
DewDiligence DewDiligence 2 years ago
FDA approves NVS’ Pluvicto*, a radioligand for CRPC:

https://www.globenewswire.com/news-release/2022/03/23/2408996/0/en/Novartis-PluvictoTM-approved-by-FDA-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-PSMA-positive-metastatic-castration-resistant-prostate-cancer.html

NVS obtained this agent from the ECYT buyout in 2018 (#msg-144295734).

*f/k/a 177Lu-PSMA-617.
👍️0
DewDiligence DewDiligence 2 years ago
FDA approves NVS’ Leqvio—(inclisiran)—for lowering LDL-C:

https://www.prnewswire.com/news-releases/fda-approves-novartis-leqvio-inclisiran-first-in-class-sirna-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year-301450125.html

NVS initially received a CRL from the FDA in late 2020 due to the FDA’s inability to conduct an inspection of the Leqvio’s manufacturing site in Italy (#msg-160327185).

Leqvio is a siRNA dosed semiannually (except for the 3-month interval between the first two doses). NVS picked up this drug when it acquired MDCO in Nov 2019 (#msg-152458295).

ALNY, which will get a 10-20% royalty on global sales, discovered Inclisiran and out-licensed it to MDCO in 2013 (#msg-84151150); with the benefit of hindsight we can say that MDCO clearly got the better of ALNY in this deal.

Leqvio was approved in the EI in late 2020 (https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year ).
👍️0
DewDiligence DewDiligence 2 years ago
NVS plans $15B share buybacks through 2023—exhausting ~70% of the proceeds from the recent sale of Roche shares:

https://finance.yahoo.com/news/novartis-initiates-usd-15-billion-060000184.html

This might be one reason XBI was down today.
👍️0
ht1 ht1 3 years ago
Novartis should invest in mRNA medicine and pair up with companies like Regen Biopharma to speed up this process. Perhaps an outright purchase of this start up company. This will ensure competing with likes of Pfizer and Moderna.
👍️0
DewDiligence DewDiligence 3 years ago
FDA_advisory_panel_endorses Entresto for_heart_failure_in_12-1_vote:

https://www.prnewswire.com/news-releases/novartis-announces-positive-fda-advisory-committee-recommendation-for-use-of-entresto-to-treat-patients-with-hfpef-301193607.html
👍️0
dshade dshade 3 years ago
good news today - Novartis Says Asciminib Showed Superior MMR Rate to Bosulif in Leukemia Trial
December 08 2020 - 11:00AM
Dow Jones News

By Michael Dabaie


Novartis AG said asciminib showed superior major molecular response rate to Bosulif in a chronic myeloid leukemia trial.

The company said results from a Phase III study demonstrate that at 24 weeks, asciminib nearly doubled the major molecular response rate compared with Bosulif in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor therapies.

The data were presented at a late-breaking abstracts session during the 62nd American Society of Hematology Annual Meeting & Exposition, Novartis said.

In the trial, 233 patients were randomized to receive asciminib 40 mg twice daily or Bosulif 500 mg once a day.

Novartis said the U.S. Food and Drug Administration granted Fast Track designation for asciminib. The company said it plans submission to U.S. and EU health authorities in the first half of 2021.
👍️0
dshade dshade 3 years ago
good news today
👍️0
DewDiligence DewDiligence 3 years ago
CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or mixed dyslipidemia:

https://www.globenewswire.com/news-release/2020/10/16/2109800/0/en/Novartis-receives-positive-CHMP-opinion-for-Leqvio-inclisiran-a-potential-first-in-class-siRNA-for-the-treatment-of-high-cholesterol.html

Rubber-stamping by the European Commission will follow in 2-3 months.
👍️0
DewDiligence DewDiligence 4 years ago
NVS/GMAB—FDA approves Kesimpta—(subcutaneous ofatumumab)—for MS:

https://finance.yahoo.com/news/u-fda-approves-kesimpta-ofatumumab-173300452.html
https://t.co/9AOLIf7Qln?amp=1

NVS acquired the commercial rights to ofatumumab from GSK, and NVS will pay GSK a tiered royalty up to 12% on worldwide sales of Kesimpta (#msg-116391951).

Ofatumumab, administered via IV, was FDA-approved for CLL under the brand name, Arzerra in 2009 (#msg-42935958).
👍️0
DewDiligence DewDiligence 4 years ago
Ofatumumab PFUFA delayed 3mo—>Sep 2020 for MS indication:

https://www.globenewswire.com/news-release/2020/06/02/2042559/0/en/Novartis-provides-update-on-FDA-review-of-ofatumumab-a-self-administered-targeted-B-cell-therapy-for-patients-with-relapsing-multiple-sclerosis.html

The PR does not cite a reason for the delay.

NVS acquired Ofatumumab’s commercial rights in MS from GSK in a 2015 transaction involving a $500M up-front payment by NVS (#msg-116391951).
👍️0
fung_derf fung_derf 4 years ago
What am I missing here? Why is no one talking about Novartis for their hydroxychloroquine?
👍️0
DewDiligence DewDiligence 4 years ago
NVS concedes Beovu has new safety issue:

https://www.brolucizumab.info/ Novartis has now completed its review of these post-marketing safety case reports… Based on internal and SRC assessment, it was concluded that there is a confirmed safety signal of rare adverse events of “retinal vasculitis and/or retinal vascular occlusion with or without presence of intraocular inflammation that may result in severe vision loss.”

Based on this review, Novartis has initiated a safety information update to Beovu prescribing information worldwide. Currently approved prescribing information includes intraocular inflammations, visual acuity decrease (including blindness) and retinal artery occlusion as separate terms. We will work with regulatory authorities to finalize the prescribing information update.

In addition, we are working with our data monitoring committees and informing investigators of ongoing clinical trials. Novartis-sponsored studies will be amended so that protocols, Informed Consent Forms and Investigator Brochures reflect this new safety information. Investigators are also being informed to re-consent patients.
👍️0
Maddog 112 Maddog 112 4 years ago
Ok thank you
👍️0
DewDiligence DewDiligence 4 years ago
It won't have any effect at all on the share price. It's a goodwill gesture and it's the right thing to do morally.
👍️0
Maddog 112 Maddog 112 4 years ago
How much will this affect the stock price 160 mil pills at 4$ is a lot of money
👍️0
DewDiligence DewDiligence 4 years ago
Yes—that was announced on Friday: #msg-154462215.
👍️0
Maddog 112 Maddog 112 4 years ago
Is it true NVS to supply 160 mil chloroquine pills to America to help fight corona virus
👍️0
DewDiligence DewDiligence 4 years ago
More on the same story (Beovu safety):

https://endpts.com/novartis-plans-to-wrestle-eylea-market-share-take-a-hit-as-beovu-is-linked-to-safety-concerns/
👍️0
DewDiligence DewDiligence 4 years ago
Acceptance of a BLA/NDA application for review doesn’t generally move the needle for a company as large as NVS unless the FDA grants a priority review when investors expected a standard review, which wasn’t the case here.
👍️0
Ecomike Ecomike 4 years ago
And so this got ignored.

https://ih.advfn.com/stock-market/NYSE/novartis-NVS/stock-news/81828953/novartis-fda-ema-accept-filings-for-ofatumumab-i?xref=ff_sidebar_quote
👍️0
DewDiligence DewDiligence 4 years ago
The cause is a safety update re Beovu (the recently approved drug for AMD):

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153989588

https://www.statnews.com/2020/02/24/safety-concerns-regarding-novartiss-new-eye-drug-boost-regeneron-stock/
👍️0
Ecomike Ecomike 4 years ago
5.5% drop on a biotech drug firm like NVS 8 days before the dividend date looks way over done to me with Biotechs in favor and nothing but Good news today and recently on NVS.

Panic selling seems way over done. But then again panics are like that.

You see any bad news at all on NVS I missed?
👍️0
DewDiligence DewDiligence 4 years ago
NVS 12/5/19 R&D Day slides:

https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf
👍️0
DewDiligence DewDiligence 4 years ago
NVS PR in conjunction with R&D Day investor webcast:

https://www.globenewswire.com/news-release/2019/12/05/1956569/0/en/Novartis-expects-to-sustain-long-term-growth-with-a-robust-pipeline-of-25-potential-blockbusters-highlighted-at-R-D-Day.html
👍️0
elotto777 elotto777 4 years ago
These shares are a BUY - Up and Away is how we would describe this company
READ REPORT HERE https://pennystocks.news/biotech-mega-merger-novartis-buys-medicines-co-9-7-billion-deal/
👍️0
DewDiligence DewDiligence 4 years ago
NVS acquires MDCO for $85/sh cash—a 64% premium to MDCO’s closing price on 11/15/19, the day before serious buyout rumors began circulating:

https://www.globenewswire.com/news-release/2019/11/24/1951667/0/en/Novartis-to-acquire-The-Medicines-Company-for-USD-9-7-bn-adding-inclisiran-a-potentially-transformational-investigational-cholesterol-lowering-therapy-to-address-leading-global-cau.html

https://www.novartis.com/sites/www.novartis.com/files/novartis-mdco-acquisition.pdf (CC slides)

The nominal deal value is $9.7B (on a fully-diluted basis). There is no CVR.
👍️0
DewDiligence DewDiligence 4 years ago
CHMP approves NVS’ Mayzent for SPMS:

https://www.globenewswire.com/news-release/2019/11/15/1947899/0/en/Novartis-receives-positive-CHMP-opinion-for-Mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-SPMS.html
👍️0
whytestocks whytestocks 4 years ago
News: $NVS ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS

NEW YORK, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business in...

Read the whole news NVS - ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS
👍️0
DewDiligence DewDiligence 4 years ago
FDA approves NVS’ Beovu—(a/k/a brolucizumab/RTH258) for wet AMD—3mo dosing interval after the loading phase:

https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html

US list price will be $1,850 per vial—inline with main competitor Eylea—according to Vantage (https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html ).
👍️0
DewDiligence DewDiligence 5 years ago
Here's the cause of today's sell-off:

https://www.wsj.com/articles/fda-says-data-manipulation-occurred-in-trials-of-world-s-priciest-drug-11565116881
👍️0
Ecomike Ecomike 5 years ago
Any clue what too the air out this one this afternoon?

I see no news yet to justify the swan dive mid day today.
👍️0
Ecomike Ecomike 5 years ago
I would love to hear more about that whole story?
👍️0
biopharm biopharm 5 years ago
Novartis been researching PS Phosphatidylserine targeting ?

Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
...
...

Dew, what do you think of the rumors swirling around PS Targeting drugs? Novartis has been swirling all around PS Targeting ever since they brought on Glen Dranoff from Dana Farber ...

Now with Dana Farber Gordon Freeman and Clive Wood enhancing patents that they collaborated on ....patents surrounding PS Targeting are key
👍️0
PennyStock Alert PennyStock Alert 5 years ago
Green after hours trading
👍️0
PennyStock Alert PennyStock Alert 5 years ago
Nice news !
👍️0
whytestocks whytestocks 5 years ago
News: $NVS AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

BASEL, Switzerland , May 24, 2019 /PRNewswire/ --   AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma ® (onasemnogene abeparvovac-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscul...

Got this from https://marketwirenews.com/news-releases/avexis-receives-fda-approval-for-zolgensma-xae-the-first-and-only-gene-therapy-for-pediatric-patients-with-spinal-muscular-atrophy-sma--8242944.html
👍️0
DewDiligence DewDiligence 5 years ago
NVS Investor Day slides:

https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-novartis-management-presentation.pdf
👍️0
DewDiligence DewDiligence 5 years ago
NVS PR accompanying today’s Investor Day webcast:

https://www.globenewswire.com/news-release/2019/05/23/1841255/0/en/Novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-on-strategy-at-Meet-Novartis-Management-investor-event.html
👍️0
DewDiligence DewDiligence 5 years ago
NVS’ QVM149* scores in phase-2 asthma trial, showing statig-better FEV1 than Advair:

https://www.globenewswire.com/news-release/2019/05/22/1840512/0/en/Novartis-phase-II-data-for-new-inhaled-combination-treatment-QVM149-demonstrates-significant-improvements-over-current-standard-of-care-inhaled-treatment.html

QVM149 is a triple-action LABA/LAMA/ICS drug administered with NVS’ proprietary Breezhaler device. The ICS component of QVM149 is licensed from MRK.
👍️0
DewDiligence DewDiligence 5 years ago
NVS acquires Xiidra from Takeda for $3.4B up-front and $1.9B in contingent milestones:

https://finance.yahoo.com/news/novartis-buys-takedas-dry-eye-223853867.html

Takeda got Xiidra, which they probably never wanted, via the 2018 acquisition of SHPG (#msg-140610505).
👍️0

Your Recent History

Delayed Upgrade Clock